13 December 2021. China’s Anhui Zhifei Longcom Biopharmaceutical said on Monday a small laboratory test showed its COVID-19 vaccine could trigger antibodies against the Omicron variant though the response was weaker than against an older virus variants.https://www.devdiscourse.com/article/health/1845016-antibody-response-from-china-zhifeis-covid-shot-weaker-against-omicron